News Releases
by Year
2018
Dec. 28, 2018 (PDF/72KB) Corporate
Correction to "Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S."
Dec. 25, 2018 (PDF/103KB) Corporate
Merger of DS Pharma Biomedical and DS Pharma Promo
Dec. 21, 2018 (PDF/127KB) R&D
Kyoto University's Center for iPS Cell Research and Application, Sumitomo Chemical, and Sumitomo Dainippon Pharma Commence Joint Research on Producing Higher-Quality iPS Cells for Clinical Use
Dec. 05, 2018 (PDF/39KB) Corporate
Sumitomo Dainippon Pharma Announces Resolution of Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S.
Nov. 27, 2018 (PDF/40KB) Corporate
Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S. (Partial correction on December 28, 2018)
Nov. 27, 2018 Sustainability
Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
Nov. 20, 2018 (PDF/2,067KB) Sustainability
ESG Meeting (Discussion with Investors)
Nov. 12, 2018 (PDF/127KB) Related Business
Announcement of the establishment of new joint company by Sumitomo Bakelite Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd.
Nov. 05, 2018 Finances
Posted Video of Investors Meeting Presentation for Q2 FY2018 [Webcast]
Nov. 02, 2018 (PDF/116KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at ASH 2018
Oct. 30, 2018 (PDF/739KB) Finances
Investors Meeting Presentation for Q2 FY2018
Oct. 30, 2018 (PDF/484KB) Finances
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2019
Oct. 30, 2018 (PDF/289KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2019 [IFRS]
Oct. 17, 2018 (PDF/118KB) R&D
Sumitomo Dainippon Pharma to Invest in and Start Joint Research and Development with MELTIN
Sep. 19, 2018 (PDF/79KB) Sustainability
Sumitomo Dainippon Pharma Contributes to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan
Sep. 10, 2018 (PDF/210KB) R&D
Results of Phase 3 Studies Evaluating Patch Formulation of Atypical Antipsychotic LONASEN Presented at Congress
Sep. 03, 2018 (PDF/129KB) Corporate
Sumitomo Dainippon Pharma announces personnel changes
Sep. 01, 2018 (PDF/228KB) R&D
FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
Jul. 31, 2018 (PDF/107KB) R&D
New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
Jul. 30, 2018 (PDF/84KB) R&D
Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin Physician-initiated Clinical Trials for Parkinson's Disease that Transplants Dopamine progenitor cells generated from Induced Pluripotent Stem (iPS) Cells
Jul. 27, 2018 (PDF/669KB) Finances
Presentation Material (First Quarter Financial Results for FY2018)
Jul. 27, 2018 (PDF/468KB) Finances
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2019
Jul. 27, 2018 (PDF/197KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2019 [IFRS]
Jul. 26, 2018 (PDF/323KB) R&D
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
Jul. 23, 2018 (PDF/80KB) Sustainability
Sumitomo Dainippon Pharma Contributes to the Relief Efforts for the Heavy Rain Event of July 2018 in Japan
Jul. 04, 2018 (PDF/86KB) R&D
Sumitomo Dainippon Pharma Submits New Drug Application for Thiotepa in Japan for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors
Jul. 02, 2018 (PDF/126KB) Products
Sumitomo Dainippon Pharma Obtains Approval in Japan for TRERIEF, a therapeutic agent for Parkinson's disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies
Jun. 28, 2018 (PDF/100KB) Sustainability
Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan
Jun. 25, 2018 (PDF/620KB) R&D
Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277) at the 2nd Pan American Parkinson's Disease and Movement Disorders Congress
Jun. 15, 2018 (PDF/127KB) Corporate
Sumitomo Dainippon Pharma announces personnel changes
Jun. 13, 2018 (PDF/438KB) R&D
Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
May 18, 2018 (PDF/119KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at EHA2018
May 17, 2018 (PDF/97KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018
May 16, 2018 Finances
Posted Video of Financial Results for FY2017 [Webcast]
May 11, 2018 (PDF/48KB) Corporate
Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions
May 11, 2018 (PDF/545KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2018
May 11, 2018 (PDF/726KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2018 [IFRS]
Apr. 26, 2018 (PDF/111KB) Finances
Sumitomo Dainippon Pharma Revises Financial Forecasts (J-GAAP) and Announces Financial Forecasts under IFRS
Apr. 25, 2018 (PDF/108KB) R&D
Sumitomo Dainippon Pharma Announces Joint Research Agreement with MMV for Identification of Antimalarial Candidate Compounds
Apr. 18, 2018 (PDF/101KB) Corporate
Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA
Apr. 04, 2018 (PDF/323KB) Products
Sunovion Announces Lonhala Magnair (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
Apr. 02, 2018 (PDF/387KB) R&D
Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson's Disease
Mar. 27, 2018 (PDF/118KB) R&D
Carna Biosciences and Sumitomo Dainippon Pharma Sign Agreement on Joint Research, Development, and Commercialization of Kinase Inhibitors
Mar. 27, 2018 (PDF/128KB) Corporate
Establishment of Shared Service Subsidiary
Mar. 07, 2018 (PDF/369KB) Products
Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
Mar. 01, 2018 (PDF/264KB) Corporate
Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy
Mar. 01, 2018 (PDF/156KB) Products
Pfizer and Sumitomo Dainippon Pharma Commence the Co-Promotion of Serotonin-Norepinephrine Reuptake Inhibitor EFFEXOR SR Capsules
Mar. 01, 2018 (PDF/175KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Feb. 26, 2018 (PDF/120KB) Licensing
Sumitomo Dainippon Pharma and JCR Sign a License Agreement on Blood-Brain Barrier Penetration Technology for Creation of a Therapeutic Agent for Central Nervous System Diseases
Feb. 24, 2018 (PDF/140KB) Corporate
SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States
Feb. 23, 2018 (PDF/254KB) Corporate
Sumitomo Dainippon Pharma Appoints Hiroshi Nomura as President and CEO
Feb. 15, 2018 (PDF/232KB) Licensing
Sumitomo Dainippon Pharma Announces Amends the License Agreement for Obeticholic Acid (DSP-1747)
Feb. 14, 2018 (PDF/287KB) R&D
Sumitomo Dainippon Pharma and Nitto Announce Positive Topline Results from Phase 3 Study Evaluating Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
Feb. 14, 2018 (PDF/89KB) Corporate
SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Patent Infringement Lawsuits Regarding LATUDA in the United States
Feb. 01, 2018 (PDF/129KB) Products
Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China
Jan. 30, 2018 (PDF/107KB) Corporate
Sumitomo Dainippon Pharma Announces Revision to its Dividend Forecast for the Year Ending March 2018
Jan. 30, 2018 (PDF/395KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2018
Jan. 30, 2018 (PDF/321KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2018 [Japanese GAAP] (Unaudited)
Jan. 30, 2018 (PDF/355KB) R&D
Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson's Disease
Jan. 05, 2018 (PDF/141KB) Corporate
Sumitomo Dainippon Pharma announces Personnel Change